idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) belong to the most common chronic inflammatory diseases (CIDs). While significant research efforts have led to improvements in treatment, there remains a lack of risk prediction tools and preventive interventions for these diseases. The European research project PerPrev-CID (Personalised Disease Prediction and Prevention in Chronic Inflammatory Disorders) sets out to fill this gap by exploring new standards for early molecular diagnosis and treatment of these diseases in order to offer patients more effective care.
The project is coordinated by the University Hospital Schleswig-Holstein (UKSH), the Faculty of Medicine at Kiel University (CAU) and the Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (PMI) and brings together 15 international research institutions from 8 countries. It will receive a total funding of 11 million Euros from the European Union’s Horizon Europe Framework Programme for Research and Innovation over the next five years. In addition, the Swiss government will contribute over 2.5 million Euros in funding for the Swiss Associate Partners.
Chronic inflammatory disease (CIDs) are disorders of the immune system, which are characterized by uncontrolled inflammation and subsequent tissue destruction in different organ systems. They place a considerable strain on patients and healthcare systems. By 2030, it is predicted that more than 10 % of the European population will be affected. At the same time, there is a considerable unmet medical need, particularly in the areas of prevention and early intervention.
Study objective: Detecting early disease progression
Therefore, PerPrev-CID aims to develop new standards for preventing and treating two prototypic CIDs rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) at an early stage. “We want to gain a deeper understanding of early disease progression focusing on mechanisms, biomarkers and innovative patient-centred outcome measures to develop actionable decision support tools for identifying individuals at risk for IBD and RA. This transformation of medicine is now in reach with innovation in molecular technologies and computational methods,” explains Professor Philip Rosenstiel, director of the Institute of Clinical Molecular Biology at UKSH and Kiel University, and scientific coordinator of the PerPrev-CID consortium.
Building on prior and ongoing EU research efforts to optimise targeted therapies, PerPrev-CID will analyse cross-sectional and longitudinal Omics-data sets (e.g. genomics, metabolomics, proteomics) as well as clinical phenotypes from patients and at-risk individuals to identify markers that predict transitions to active disease, disease progression and early disease relapse. To better monitor individual disease progression and patients’ well-being, PerPrev-CID also develops safe digital health technologies such as wearables and apps to track a range of objective health indicators, and enable continuous, digital monitoring of patient data. The network will develop innovative biomarkers from home-based sampling methods of biomaterials such as blood and stool. Furthermore, the project will assess the effectiveness of a nutritional intervention targeting the tryptophan metabolic axis in preventing disease flares and progression in early RA and IBD.
Patient-centred research for maximal patient outcomes
“A shift towards earlier interventions is now crucial to maximise patient outcomes,” says Stefan Schreiber, Director of the Dep. of Internal Medicine I at UKSH, Kiel Campus, and speaker of the Cluster of Excellence PMI, who is leading the clinical intervention part in PerPrev-CID. “If we really want to transform our approach to these disorders, we have to develop rationale, low-threshold health-promoting interventions in individuals at risk to re-program disease at the earliest possible time point.”
Through these efforts and a strong focus on patient involvement, the project significantly contributes to empowering patients and advancing patient-centred research. “We aim to challenge the traditional top-down approach in medical research by promoting co-creation, where patients and individuals at risk of RA or IBD are engaged as active stakeholders throughout the research process. This involvement empowers them to actively participate in decisions regarding their health,” says Rosenstiel. Moreover, PerPrev-CID will provide health professionals with advanced tools and scientifically validated data on omics, diet, and lifestyle factors, enabling personalised patient care. These resources will serve as blueprints for future personalised healthcare initiatives, advancing patient-centred clinical practice.
Project Key Facts:
Title: Personalised Disease Prediction and Prevention in Chronic Inflammatory Disorders (PerPrev-CID)
Start: 1 January 2025
Duration: 60 months
Budget: € 11 Mil. + € 2.5 Mil. (Swiss government)
Coordinator: University Hospital Schleswig-Holstein (UKSH), Germany
Website: www.perprev-cid.eu
LinkedIn: www.linkedin.com/showcase/perprev-cid
PerPrev-CID Partners
Belgium
• European Federation of Crohn`s And Colitis Associations
• Université de Liège
• VIB VZW
Germany
• Kiel University
• Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) e.V.
• EURICE – European Research and Project Office GmbH
• University Hospital Schleswig-Holstein, Campus Kiel (UKSH)
Israel
• Weizmann Institute of Science
Italy
• Università Cattolica del Sacro Cuore
Lithuania
• Lietuvos Sveikatos Mokslu Universitetas
• Lietuvos Sveitakos Mokslu Universiteto Ligonine Kauno Klinikos
Netherlands
• Stichting Radboud Universiteit
Switzerland
• European Alliance of Associations for Rheumatology
• Université de Genève
UK
• The University of Manchester
(Press text: Kerstin Nees, Kiel University, Press Office)
Project Coordinator:
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Institute of Clinical Molecular Biology, Prof. Dr. Philip Rosenstiel
p.rosenstiel@mucosa.de
Project Management:
EURICE – European Research and Project Office GmbH
Dr Lorena Consolino
l.consolino@eurice.eu
Prof Dr Philip Rosenstiel, Director of the Institute of Clinical Molecular Biology at the UKSH, Kiel ...
SoulPicture
Merkmale dieser Pressemitteilung:
Journalisten, Wissenschaftler
Ernährung / Gesundheit / Pflege, Medizin
überregional
Forschungsprojekte, Kooperationen
Englisch
Prof Dr Philip Rosenstiel, Director of the Institute of Clinical Molecular Biology at the UKSH, Kiel ...
SoulPicture
Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).
